DR. FRANK LYONS GREENWAY, M.D.
Osteopathic Medicine in Baton Rouge, LA

6417231, Jul 9, 2002

Dec 18, 1997

08/992852

Frank L. Greenway - Baton Rouge LA 70810
Jennifer C. Rood - Baton Rouge LA 70820

A61K 3122

514546, 514529, 554123, 554115

A method and composition are disclosed for administering pyruvate in high doses to mammals, including humans. The method and composition do not produce an excessive acid load, salt load, or nitrogen load. Bioavailability of pyruvate from the composition is high. The composition has been named “tripyruvin” (tripyruvyl glycerol, or glycerol tripyruvate), and has the following structure:.

7150141, Dec 19, 2006

Nov 14, 2003

10/713518

Frank L. Greenway - Baton Rouge LA, US
Andrew T. Roberts - Baton Rouge LA, US

Board of Supervisors of Louisiana State University Agricultural & Mechanical College - Baton Rouge LA

A44C 11/00, A61B 5/11, B21L 1/00, G01G 19/44

59 1, 2321, 272 93, 54 23, 3405737, 3405554

Presented in one embodiment is a waist chain comprising a plurality of links; a plurality of coupling members which connect the plurality of links, thereby forming a chain with two ends; and at least one end connection member which is connectable to both ends of the chain such that the chain becomes continuous. The waist chain is positioned tightly around the waist of a person such that as the person's weight increases, the waist chain becomes increasingly tight. Presented in another embodiment is a waist chain comprising a plurality of links; a plurality of coupling members which connect the plurality of links, thereby forming a chain with two ends; at least one end connection member which is connectable to both ends of the chain such that the chain becomes continuous and at least one end link which is connectable to one or both ends of the chain and to the end connection member. The end connection member is a hollow cylinder comprising a side wall. Presented in another embodiment is a weight loss method comprising altering a person's food intake such that the person experiences weight loss; fitting the person tightly with a waist chain such that as the person's weight increases, the waist chain becomes increasingly tight.

7709031, May 4, 2010

May 27, 2004

10/559091

Frank L. Greenway - Baton Rouge LA, US
Zhijun Liu - Baton Rouge LA, US
Eugene A. Woltering - Kenner LA, US

Board of Supervisors of Louisiana State University And Agricultural and Mechanical College - Baton Rouge LA

A61K 36/00, A61K 51/00, A61K 39/395, A61K 38/21

424725, 424 169, 4241451, 424 854

An extract of Chinese blackberry () has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.

2007002, Jan 25, 2007

Jun 8, 2006

11/449417

Frank Greenway - Baton Rouge LA, US
Linda Young - Montara CA, US

A61L 9/04, A61K 31/4745, A61K 31/4166, A61K 31/137, A61K 31/24

424045000, 514305000, 514389000, 514536000, 514649000

Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense of smell or taste in subjects prior to meals leads to decreased food intake, which ultimately leads to weight loss. The ability to deliver drugs to the CSF via intranasal application also provide anorexiant central effect.

2007002, Jan 25, 2007

Jun 8, 2006

11/449418

Frank Greenway - Baton Rouge LA, US
Michael Cowley - Portland OR, US
Linda Young - Montara CA, US

A61L 9/04, A61K 31/522, A61K 31/4745, A61K 31/4166, A61K 31/165, A61K 31/137

424045000, 514263310, 514373000, 514536000, 514618000, 514649000, 514305000, 514389000

Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense of smell or taste in subjects prior to meals leads to decreased food intake, which ultimately leads to weight loss. The ability to deliver drugs to the CSF via intranasal application also provides anorexiant central effect.

2011014, Jun 16, 2011

Aug 13, 2009

13/058762

Alexander McLellan - Halifax, CA
Frank Greenway - Baton Rouge LA, US

A61K 31/351, A61K 31/045, A61K 31/122, A61K 31/19, A61K 31/22, A61P 25/00, A61P 25/02

514451, 514739, 514678, 514557, 514549

Compositions comprising terpene compounds for the treatment of negative sensory phenomena (NSP). Negative sensory phenomena is characterized by a decreased ability to sense light touch, pin prick, vibration, temperature, pain and/or reduced proprioception. The terpene compounds are preferably aromatic terpene compounds such as geraniol and citronellol and analogs thereof. The terpenes may also be used in combination. The terpenes are derived form plant essential oils or are manufactured synthetically.

2011025, Oct 20, 2011

Aug 6, 2009

12/537095

Alexander McLellan - Halifax, CA
Frank Greenway - Baton Rouge LA, US

A61K 31/045, A61P 25/00, A61K 31/22, A61K 31/122, A61K 31/351, A61K 31/11

514451, 514739, 514703, 514529, 514546, 514549, 514690, 514729

The presently claimed and disclosed invention(s) provides a therapeutically effective composition and method of inhibiting nerve cell transmission. In a preferred embodiment of the presently claimed and disclosed invention(s), the treatment of neuropathic pain utilizing terpene compounds isolated from plant essential oils or manufactured synthetically is detailed. These compounds, such as geraniol and citronellol, as well as chemical analogs thereof, used in combination or individually, can be used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form.

2012007, Mar 22, 2012

Mar 28, 2011

13/073135

Frank L. Greenway - Baton Rouge LA, US
Zhijun Liu - Baton Rouge LA, US

A61K 31/704, A61P 7/06, A61P 35/00, A61P 31/04, A61P 19/04, A61P 25/00, A61P 19/08, A61P 7/00, A61P 17/06, A61P 29/00, A61P 27/10, A61P 33/02, A61P 27/02, A61P 1/00

514 33

Extracts of radix platycodin are used to inhibit angiogenesis, particularly angiogenesis that is associated with disease conditions other than obesity or cancer.